Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$14.33 - $18.37 $260,806 - $334,334
-18,200 Closed
0 $0
Q3 2022

Nov 14, 2022

BUY
$13.07 - $18.22 $237,874 - $331,604
18,200 New
18,200 $287,000
Q3 2019

Nov 14, 2019

SELL
$0.79 - $2.47 $208,471 - $651,803
-263,888 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$2.13 - $7.06 $711,999 - $2.36 Million
-334,272 Reduced 55.88%
263,888 $578,000
Q1 2019

May 14, 2019

BUY
$5.63 - $7.84 $1.22 Million - $1.7 Million
216,212 Added 56.61%
598,160 $3.58 Million
Q2 2018

Aug 13, 2018

BUY
$16.46 - $20.33 $1.44 Million - $1.77 Million
87,250 Added 29.61%
381,948 $7.63 Million
Q1 2018

May 14, 2018

BUY
$17.08 - $25.64 $562,598 - $844,555
32,939 Added 12.58%
294,698 $5.16 Million
Q4 2017

Feb 13, 2018

BUY
$21.47 - $27.8 $5.62 Million - $7.28 Million
261,759
261,759 $6.46 Million

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $253M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.